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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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Pharmaceutical giant Roche’s September 16 announcement of the 2019
start of its Phase 3 Huntington’s disease clinical trial has raised great
expectations about whether this drug could be the first effective treatment
for this devastating disorder.
The short answer: it’s still too soon to tell.
During a September 26 Huntington’s Disease Society of America (HDSA)
hour-long webinar on the trial, Roche representatives received hundreds
of questions via chat from HD community members. They had time to
answer only a few, with HDSA pledging to compile and post answers to
unanswered questions on its website soon. (Click here to watch the
webinar.)
Likewise, in response to my September 16 posting about the Roche
announcement, many people in Facebook HD discussion groups have
sought further information about the trial.
Roche plans to test the efficacy of RG6042, a gene-silencing drug aimed at
slowing, halting, and perhaps even reversing HD symptoms, in 660
volunteers over 25 months. The test will take place at 80 to 90 sites in
approximately 15 countries. Each month, participants will receive the drug
or placebo through a lumbar puncture. Roche will announce the sites
gradually in the coming months.
Roche has named the study GENERATION HD1 (short for Global
EvaluatioN of Efficacy and safety of Roche/genentech AnTIsense
OligoNucleotide for Huntington’s Disease).
Let me try to address some of the key questions about the trial from the
HD community, as well as my own relationship to it as a presymptomatic
HD gene carrier.
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Scott Schobel, M.D., M.S. (left), Roche clinical science leader of product
development, announces GENERATION HD1 at the European
Huntington's Disease Network Meeting in Vienna, Austria, on September
16, 2018 (photo courtesy of HDBuzz.net).
‘How do I sign up?’
A frequent question from the community: “How do I sign up for the trial?”
During the webinar, Roche officials stressed that patients should consult
with their HD doctors and families about eligibility for the trial, the pros
and cons of participation, and logistics such as transportation or relocation
to a trial site.
J. P. Sacksteder, of Genentech Advocacy Relations, said that Roche will
announce the sites as each becomes ready to enroll patients. (Genentech, a
major U.S.-based biotech firm, was acquired by the Swiss-based Roche in
2009. All U.S-based Roche personnel and products still use the name
Genentech.)
“We ask for your patience and understanding as we share these trial sites,”
Sacksteder said, noting that many factors influence site selection,
including experience in conducting HD studies. “We understand that each
of your situations is unique, so please continue to discuss your situation
with your HD specialist.”
Erik Lundgren, lifecycle leader of the Roche HD program, recognized the
great “desire” of HD-affected individuals to take part, but also pointed out
the substantial “commitment” required in a rigorous, 25-month clinical
research project.
Clinicaltrials.gov and HDTrialfinder.org will provide the latest information
on GENERATION HD1.
Roche officials further noted that participants could continue taking most
HD-related medications, including anti-depressants as well as drugs to
control involuntary movements such as Austedo and Xenazine. Excluded
drugs are memantine and riluzole. Participants must start any new
regimen of medicines at least three months prior to the trial’s start.
Individuals cannot participate in a concurrent trial, but are not barred if
they had participated in past HD trials.
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For those aged 25-65
Roche will recruit volunteers who are between the ages of 25 and 65 at the
start of the trial, explained Scott Schobel, M.D., M.S., Roche clinical
science leader of product development.
Based on statistical studies of the HD population, people in the 25-65 age
group have a more predictable progression of symptoms than younger or
older groups, Dr. Schobel explained. Focusing on that cohort, he said, will
furnish trial researchers with the best, most efficient way to measure
whether RG6042 alleviates symptoms.
The later a person’s motor onset, the standard diagnosis of HD, the
“potentially less of a progression of symptoms over time,” he added. Motor
symptoms involve involuntary movements and imbalance.
Thus, including people over 65 in GENERATION HD1 would be less
helpful to researchers trying to gauge the drug’s impact.
Dr. Schobel’s assertion about later motor onset reassured me a bit
regarding my own potential disease progression as an HD gene carrier. At
my latest HD checkup earlier this year, I had not shown such symptoms.
My HD-stricken mother’s onset occurred probably in her late 40s, and by
age 58 (my current age) she had full-blown HD. She died at 68.
I hope that the lack of motor symptoms at this stage means that, after my
inevitable onset, I, too, will have a lesser progression of symptoms.
Healthy gene carriers excluded
However, I can’t participate in GENERATION HD1, because, at this time,
presymptomatic gene carriers are ineligible. My question during the
webinar requesting further details about this wasn’t answered.
In general, presymptomatic gene carriers haven’t been invited to
participate in most HD clinical trials because it’s hard to measure a drug
effect on an apparently healthy person.
There are also safety and ethical concerns in involving healthy individuals
in a complex clinical trial like GENERATION HD1 – for example, exposing
a healthy person to the potential side effects of the trial.
Regarding presymptomatic individuals and also the excluded juvenile HD
population, Roche stated in its September 16 announcement: “We
recognize the critical medical need for a treatment for HD, especially for
people living with severe forms like juvenile onset HD. In consultation
with HD community experts, our team will explore the potential use of
curehd.blogspot.com/2018/09/unpacking-generation-hd1-roche-phase-3.html
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RG6042 in populations beyond manifest [symptomatic] HD once there is
sufficient scientific and safety rationale.”
At the September 16 announcement of GENERATION HD1, Dr. Schobel
pointed out that the drug might act differently in the still developing
brains of children and young people.
The ultimate goal of researchers is to develop a preventive treatment.
Concerns about frequent spinal taps
Even if eligible, I would have to seriously consider the risks of undergoing
the lumbar punctures. The punctures, also known as spinal taps, introduce
the drug into an individual’s cerebral spinal fluid (CSF) and allow
researchers to withdraw some CSF for analysis.
Lumbar punctures are routine and generally safe procedures, although
they can cause side effects such as headaches and bleeding. The 46
subjects in the Phase 1/2a trial of RG6042, completed in December 2017,
had few side effects. Ed Wild, M.D., Ph.D., who conducts research on the
CSF in HD, underwent the procedure as a demonstration for the HD
community
Still, I’m personally concerned about the lumbar puncture, which, if a
medicine is approved, would likely be the initial pathway for it to be
administered.
In 1977, at age 17, I suffered two herniated disks in my lower spine while
shoveling heavy snow in my hometown of Mentor, Ohio. Ever since, I have
struggled with low back pain.
An MRI (magnetic resonance imaging) scan ten years ago revealed that the
disks mainly healed, but I suffer daily with muscular pain, or myofascial
pain syndrome. Occasionally, severe flareups prevent me from walking and
performing some daily activities.
Since that MRI, I’ve consulted regularly with pain management specialists.
I’ve also worked with physical therapists to incorporate other exercises
into my morning stretching routine to strengthen my core and back.
Along with daily aerobic exercises, I want to stay strong and flexible to help
forestall my inevitable HD onset and, later, to help ameliorate symptoms.
Alternative drug delivery methods?
In 2013, as a participant in the PREDICT-HD (Neurobiological Predictors
of Huntington’s Disease) research project at the University of Iowa, I
considered a request to provide a sample of my CSF.
After reviewing my lower spinal MRI, a doctor at Iowa concluded that a
lumbar puncture was too risky.
Also, had I suffered any complications after the procedure, I would have
had to obtain medical care not in Iowa, but only after returning to my
current hometown of San Diego, where I have health coverage.
I wanted to assist with the research, but ultimately believed that the
potential risks outweighed the benefits.
Given these concerns, during the webinar I posed two questions regarding
the spinal taps. First, what will Roche due to minimize the impact of the 25
monthly procedures? Secondly, how will Roche address the fact that many
people in the U.S. suffer from lower back problems?
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I look forward to hearing Roche’s ideas, including the latest research on
alternatives to spinal taps such as Roche’s “brain shuttle”
technology and/or devices for delivering the drug.
If back pain is part the price for an effective HD treatment, I am willing to
endure it.
Timeline and cost
Another major concern of the community: if GENERATION HD1 is
successful, when might drug approval come?
“I can’t ultimately commit to what that timeline looks like,” Lundgren said.
“We are doing everything we can to speed it up.”
First, Roche must enroll all 660 volunteers. “That’s a big variable,” he said.
“We can’t complete the study until 25 months after the last patients receive
their first dose.”
Then researchers must organize and analyze the data. If the latter appear
promising, then Roche must seek regulatory approval from the U.S. Food
and Drug Administration and similar agencies around the world.
According to a September 17 article on the scientist-produced site HDBuzz,
“Not every patient enrolls on the first day of the trial, so a trial in which
each participant is involved for 25 months will take around twice that long
to run, and possibly longer.”
It’s also too early to project the cost of the potential drug, Lundgren said.
He added that Roche is committed to providing access to those with
inadequate insurance.
Working towards the best treatments
Dr. Schobel addressed concerns about the fact that RG6042, developed by
Ionis Pharmaceuticals, Inc., is designed to reduce both the harmful mutant
huntingtin protein involved in HD and normal huntingtin, essential in cell
function.
According to Dr. Schobel, the drug’s effect “fundamentally is partial and
can reverse and is titratable [adjustable], versus those kinds of
experiments that are in the scientific literature, which shut off the gene
100 percent. That is not what we’re doing, for either the mutant protein or
the so-called normal or total levels of protein. We have the ability to find a
sweet spot potentially where there’s benefit and less risk, or even pause
dosing.”
The Roche-Ionis approach differs from the two current Phase 1b/2a
clinical trials by Wave Life Sciences, whose drugs target only the harmful
protein by using genetic markers present in most but not all people with
HD. (Click here to watch a presentation on the trials by Wave’s Michael
Panzara, M.D., MPH.)
These and other clinical trials seek to find the best approach. Scientists
have said that a combination of approaches, or an “HD cocktail,” may be
needed to treat this complex disease.
(I hold a symbolic amount of Ionis shares.)
This article is dedicated to the many donors and walkers who supported
the Serbin Family Team in the 2018 HDSA-San Diego Team Hope Walk,
held today. See photos below. Thanks to you, we raised over $4,000
towards the care and cure of HD! You can still donate by clicking here.
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The Serbin Family Team of the 2018 Hope Walk: above, from left to right,
Lance Ramsey, Adi Drapkin, Alexandra Drapkin, Regina Serbin, Gene
Veritas (aka Kenneth P. Serbin), Maria Ramos, Peter Kim, Yuka Kim, and
Lily Kim (in stroller). Below, from left to right, Tom Johnson, Yuka Kim,
Peter Kim, Lily Kim (in stroller), Judy Melville, Gene Veritas, Patrick
Melville, Sean Naficy, and Sam Melville (personal photos).

Posted by Gene Veritas at 6:12 PM
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